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gained. RESULTS: Patients were categorized into 5FU/LV (n = 2,834), oxaliplatin 
based (n = 621), and irinotecan based (n = 945) subgroups, based on the regimen they 
received. The median improvement in overall survival with 5FU/LV, irinotecan or 
oxaliplatin based combination therapy was 1.25, 1.34, and 1.72 life-years, respec-
tively. The incremental cost with irinotecan or oxaliplatin based combination therapy 
compared with 5FU/LV was $205,837 and $93,651, respectively. When comparing 
to irinotecan based combination therapy, the incremental cost-effectiveness ratio 
of oxaliplatin based combination therapy was $67,637 per life-year gained. 
CONCLUSIONS: This analysis suggests that oxaliplatin or irinotecan based combina-
tion therapy improves overall survival but also substantially increases direct medical 
costs compared with 5FU/LV when used in elderly US patients with stage IV colon 
cancer. Oxaliplatin-based regimens are more cost-effective than irinotecan based 
regimens.
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OBJECTIVES: The cost-effectiveness of cetuximab has been controversial mainly 
because of its marginal clinical beneﬁts at very high medication cost. This study 
examines the cost-effectiveness of cetuximab versus best supportive care in the patients 
with metastatic colorectal cancer in US from the perspective of Medicare. METHODS: 
As modeled in a decision tree, three treatment options (cetuximab, cetuximab plus 
irinotecan, and best supportive care) are evaluated clinically and economically. Costs 
of cetuximab treatment options are largely determined by the treatment responses: 
complete or partial responsive, stable disease, or progressive, and whether or not the 
patient experienced severe infusion reaction and/or severe adverse events. The primary 
outcome is quality-adjusted life expectancy. The treatment response rates and quality 
of life measurements are based on the results from clinical trials. Incremental cost-
effectiveness ratios (ICER) between cetuximab treatments and best supportive care are 
presented to demonstrate the value of cetuximab treatments. Finally, sensitivity analy-
ses are conduct to test the robustness of the results. RESULTS: In the patients with 
metastatic colorectal caner, the incremental cost per quality-adjusted life year (QALY) 
was $336,218 for cetuximab, and $318,609 for cetuximab plus irinotecan, in com-
parison with best supportive care. One-way sensitivity analyses showed that the cost 
of cetuximab had the highest impact on ICERs, compared to other costs and quality 
of life parameters. Probabilistic sensitivity analyses by Monte Carlo simulation dem-
onstrated that best supportive care is more cost-effective than cetuximab treatments 
until the threshold of willingness to pay is raised up to $240,000. CONCLUSIONS: 
Our analyses suggest that cetuximab is not cost-effective, either in monotherapy or in 
combination with irinotecan, as the cost-effectiveness ratios are far beyond the 
accepted threshold of $50,000 per QALY gained. Cetuximab treatments need to be 
carefully evaluated before being delivered to metastatic colorectal cancer patients.
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OBJECTIVES: The beneﬁt of screening for and deﬁnitive treatment for prostate cancer 
has been questioned. Results from the Scandinavian study of radical prostatectomy 
compared to watchful waiting for non-screen detected prostate cancer demonstrated 
decrease in prostate cancer speciﬁc mortality, palliative treatment and overall survival. 
We evaluated the cost effectiveness of radical prostatectomy compared to watchful 
waiting using data from the Scandinavian study protocol when extrapolated to the 
US. METHODS: We used the previously reported cost of care data for patients with 
prostate cancer based on the patterns of care observed in the CaPSURE database. The 
data from the Scandinavian trial, in accordance with the study protocol, was used to 
determine the costs and cost-effectiveness of radical prostatectomy for treatment of 
prostate cancer. The cost-effectiveness for radical prostatectomy was determined and 
was adjusted for the costs of androgen deprivation therapy as used in each study arm. 
A model incorporating age at diagnosis, life expectancy and estimate of beneﬁts from 
radical prostatectomy was created that predicts cost effectiveness of surgical interven-
tion for prostate cancer. A sensitivity analysis was performed to test the robustness 
of results. RESULTS: Compared to watchful waiting, radical prostatectomy is associ-
ated with savings of $92,259 per life saved or $4,128 per LYS. When the rate of 
treatment with ADT in each study arm is taken into account, radical prostatectomy 
for treatment of non-screen detected prostate cancer is associated with cost savings of 
$475,297 per life saved or savings of $27,959 per life-year saved compared to the 
costs of watchful waiting. CONCLUSIONS: Radical prostatectomy is a cost effective 
treatment for non-screen detected prostate cancer. Treatment with radical prostatec-
tomy is associated with signiﬁcant cost savings, improved survival, decreased rate of 
metastatic disease and lower rate of palliative care compared to watchful waiting. For 
patients who are surgical candidates watchful waiting is associated with higher mor-
bidity, mortality and costs.
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OBJECTIVES: Compare cost-effectiveness of three non-melanoma skin cancer 
(NMSC) strategies: all Mohs Micrographic Surgery (MMS), all surgical excision and 
mixed MMS and excision. METHODS: A decision-analytic model compared strate-
gies using data from a prospective sample (n = 540) treated with MMS or excision at 
a university-afﬁliated dermatology clinic from 1999–2000. The newest (2007) Medi-
care costing rules with tumor size, location and number of stages for MMS were used. 
Total cost included the procedure, pathology, drugs, 2 month follow-up visits, second-
ary procedures, repairs or grafts and recurrences. Short Form (SF)-12 and Skindex 
scores at baseline and 2 years were mapped to the Health Utility Index (HUI) to adjust 
life expectancy and recurrence, our major outcomes. Cost per quality adjusted life 
year saved (QALYS) was the ﬁnal outcome. Sensitivity analysis tested uncertainty of 
model parameters. RESULTS: The all MMS strategy was most cost-effective when 
compared to mixed (ICER = $30,521/QALYS) and all excision strategies (ICER = 
$6,722/QALYS). The mixed strategy was cost-effective compared to the all excision 
strategy (ICER = $1,924/QALYS). All excision was least costly ($1634.50/patient), 
mixed next ($1681.00/patient) and all MMS was most costly ($1830.10/patient). The 
all MMS strategy (17.2081 QALYS) was most effective compared to mixed (17.2032 
QALYS) and all excision (17.1790 QALYS) strategies. The model is sensitive to the 
proportion of patients who receive MMS versus excision in the mixed strategy. The 
all MMS strategy no longer is cost-effective compared to the mixed strategy when the 
MMS proportion is decreased from 58.8% to 50% (ICER = $2,793,794) and at 45% 
the mixed strategy dominates all other strategies. Not until $900 is added to procedure 
cost for MMS, does the all MMS strategy lose its cost-effectiveness. CONCLUSIONS: 
All MMS for NMSC is the most cost-effective strategy although the mixed strategy is 
preferred in some mixtures of patient populations. This analysis demonstrates that 
MMS is cost-effective if clinically indicated.
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OBJECTIVES: Sorafenib is the only agent that has proven to improve survival in 
AHCC (Llovet, NEJM 2008), and has been considered cost-effective in Canada 
(Muszbek, Curr Med Res Opin 2008), when compared with BSC. In clinical practice 
in Brazil, however, patients with AHCC with no access to sorafenib are often treated 
with other systemic agents, none of which are able to improve the outcome. The objec-
tive of this study was to evaluate the cost-effectiveness of sorafenib+BSC vs BSC alone 
in Brazil, from the perspective of the public health-care system. METHODS: A Markov 
model was developed to project the lifetime survival and costs for both interventions 
using data from the TTP and OS Kaplan-Meier curves from SHARP trial using a log-
normal distribution and an ad hoc panel with Brazilian medical oncologists, hepatolo-
gists, and liver surgeons. Treatment effectiveness was measured in life-years gained 
(LYG). Resource utilization included drug, administration, physician visits, monitor-
ing, and adverse events. Costs (in R$, with R$ 1.00 ∼ US$ 0.58) and survival beneﬁts 
were discounted annually at 5%. Univariate and probabilistic sensitivity analyses were 
conducted. RESULTS: Lifetime per-patient costs in R$ (US$) were 76,032 (43,447) and 
9,776 (5,586) for sorafenib+BSC and BSC alone, respectively. Sorafenib drug cost 
accounted for nearly 79% of treatment costs. The incremental survival beneﬁt with 
sorafenib+BSC was 0.49 life-years. The incremental cost-effectiveness ratio of 
sorafenib+BSC vs BSC alone was R$ 135,262 (US$ 77,293) per LYG. Variations in the 
lognormal parameters for OS of both alternatives demonstrated to be the most inﬂu-
ential variables in the cost-effectiveness result in the deterministic sensitivity analysis. 
CONCLUSIONS: The addition of sorafenib to BSC is the only intervention that has 
been found to improve survival in AHCC and the cost-effectiveness results should be 
interpreted considering the low cost and inefﬁciency of the comparator.
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OBJECTIVES: Multiple myeloma (MM) is a hematologic malignancy mainly affecting 
the elderly population. It is incurable and patients experience a considerable reduction 
of health-related-quality-of-life (HRQoL). Some newer therapies have shown better 
clinical effects but are more costly. Pharmacoeconomic studies on MM have been 
widely conducted overseas but local data was lacking. This study aimed to examine 
the cost-effectiveness of the treatments for MM in Macao, China. METHODS: A 
retrospective cost-effectiveness study with HRQoL assessment was conducted. Forty 
patients from the largest public hospital in Macao from 1997–2007 with conﬁrmed 
MM were studied. Data for costs and treatment effects were extracted from patients’ 
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medical records including disease characteristics, treatment regimens, medications 
used and treatment outcomes. The study was conducted from the perspective of a 
Macao public hospital. The European Organization for Research and Treatment of 
Cancer quality-of-life questionnaire (EORTC QLQ-C30) (version 3.0, Chinese-Hong 
Kong) was used for the HRQoL assessment. RESULTS: The standard-dose melphalan-
based and vincristine-doxorubicin-dexamethasone-based regimens (VAD) were the 
most common treatment regimens. There were 24 and 10 patients in the melphalan-
based and VAD-based group respectively. Six patients were not studied due to incom-
plete data. Patients in the melphalan-based group were at a more advanced age (70.4 
± 7.4 years; p < 0.001). The melphalan-based group showed a lower overall treatment 
cost (MOP 29,231 versus MOP 44,831; p = 0.521, 1 USD = 8 MOP), especially on 
inpatient medication cost (MOP 5,809 versus MOP 13,908; p = 0.096). The VAD-
based group showed better clinical outcomes than the melphalan-based group in terms 
of overall survival, progression-free survival and survival probability with time. The 
incremental cost-effectiveness ratio of VAD-based regimens compared with melpha-
lan-based regimens was MOP 6,695 per life-year-gained. CONCLUSIONS: The 
results of this study suggest that the VAD-based regimens are very cost-effective 
according to the WHO recommended thresholds for cost-effectiveness in patients with 
MM in Macao.
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SURGERY FOR PATIENTS WITH COLON RECTAL CANCER:  
A COST EFFECTIVENESS ANALYSIS, UNDER THE BRAZILIAN  
PRIVATE PAYER PERSPECTIVE
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OBJECTIVES: To compare costs and outcomes of surgery techniques [open (OP) 
versus laparoscopic (LAP)] for colon rectal surgery in order to assess the impact on 
costs and clinical outcomes under the private payer perspective in Brazil. METHODS: 
A decision tree and a Markov model were developed according to the Brazilian 
guidelines for Health Technology Assessment (Vianna, 2007). Outcomes rates and 
probabilities for infection, mortality, conversion, survival, recurrence, sepsis and 
hernia were obtained from clinical literature (Gunnarsson 2008, King 2006, Bonjer 
2009, Murray 2006, Brazilian consensus for Sepsis 2003). A panel of specialists was 
conducted to validate the model and capture the local practice. Only direct medical 
costs were considered (Sources: SIMPRO, 2009; CBHPM 5th edition). A lifetime 
perspective was taken and a discount rate of 5% was applied (Vianna, 2007). A 
probabilistic sensitivity analysis was performed to assess the robustness of the results. 
RESULTS: Lengh of staying (LOS) was 9 days for OP versus 6 days for LAP resulting 
in a reduction of hospital costs and medical staff fees (R$5687 OP versus R$4445 
LAP). LAP also reduced the complication costs in 70% (-R$ 981 per procedure). Total 
costs were 8.52% higher for LAP than OP (R$22,085 vs. R$ 20,350), because of 
LAP’s devices costs (R$17,228 vs. R$13,270). In terms of outcomes, due mainly to 
the reduction of infection rate (OP 4.09% vs. 2.11% LAP) and the reduction of sepsis 
cases in 48.41% LAP showed an improvement on overall survival (1.31 years without 
discount and 0.36 years discounted). The sensitivity analysis showed that over 65% 
of the 5000 simulation were cost-effective. 1 USD = R$ 1.78 CONCLUSIONS: Find-
ings suggest LAP as a safer and cost-effective choice for colon cancer surgeries when 
compared with OP.
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OBJECTIVES: To examine the cost-utility of using KRAS mutation testing prior to 
initiating cetuximab monotherapy for patients with metastatic colorectal cancer 
(mCRC) from a US payer perspective. METHODS: A decision analytic model was 
developed to evaluate the clinical and economic impact of three strategies for treating 
mCRC, 1) cetuximab monotherapy; 2) Best supportive care (BSC); and 3) KRAS 
mutation testing with cetuximab for KRAS wild type patients and BSC for patients 
harboring a KRAS mutation. Model parameters were derived from the CO.17 trial, 
published literature, and government sources. The model included trial-based survival 
estimates and adverse event rates as well as costs related to drug treatment and 
administration, KRAS testing, adverse events, and post-progression care. The model 
results were examined using one-way and probabilistic sensitivity analyses. RESULTS: 
Total QALYs for the cetuximab, BSC, and KRAS testing strategies were 0.47, 0.36, 
and 0.47, respectively. Total costs were $44,301; $6,364; and $34,263, respectively. 
Relative to BSC, cetuximab for all and KRAS testing strategies had incremental cost-
effectiveness ratios of $357,224 and $264,644 per QALY, respectively. Relative to 
cetuximab for all, the KRAS testing strategy saved $10,037 with a negligible decrease 
in QALYs. One-way sensitivity analyses found the results to be most sensitive to the 
survival estimates, cost of cetuximab, and the pre progression utility score. In the 
probabilistic sensitivity analysis, BSC had the highest probability of being cost-effec-
tive until a willingness-to-pay of $275,000, after which KRAS testing had the highest 
probability. CONCLUSIONS: These results suggest that the use of KRAS testing to 
select patients for cetuximab treatment in mCRC can reduce costs with a negligible 
impact on QALYs as compared to using cetuximab for all patients. However, the 
cost-effectiveness of KRAS testing vs. best supportive care remains well above com-
monly used cost-effectiveness thresholds.
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OBJECTIVES: Sorafenib improves survival in AHCC (Llovet, NEJM 2008), and has 
been considered cost-effective in Canada (Muszbek, Curr Med Res Opin 2008), when 
compared with BSC. In clinical practice, however, patients with AHCC with no access 
to sorafenib are often treated with other systemic agents, none of which are able to 
improve the outcome. The objective of this study was to evaluate the cost-effectiveness 
of sorafenib+BSC vs BSC alone in Brazil, from the perspective of the private health-
care system. METHODS: A Markov model was developed to project the lifetime 
survival and costs for both interventions using data from the TTP and OS Kaplan-
Meier curves from SHARP trial in a lognormal distribution and from an ad hoc panel 
with Brazilian medical oncologists, hepatologists, and liver surgeons. Treatment effec-
tiveness was measured in life-years gained (LYG). Resource utilization included drug, 
administration, physician visits, monitoring, and adverse events. Costs (in R$, with 
R$ 1.00 ∼ US$ 0.58) and survival beneﬁts were discounted annually at 5%. Univariate 
and probabilistic sensitivity analyses were conducted. RESULTS: Lifetime per-patient 
costs in R$ (US$) were 103,210 (58,977) and 10,435 (5,963) for sorafenib+BSC and 
BSC alone, respectively. Sorafenib drug cost accounted for nearly 80% of treatment 
costs. The incremental survival beneﬁt with sorafenib+BSC was 0.49 life-years. The 
incremental cost-effectiveness ratio of sorafenib+BSC vs BSC alone was R$ 189,402 
(US$ 108,230) per LYG. CONCLUSIONS: The addition of sorafenib to BSC is the 
only intervention that has been found to improve survival in AHCC and the cost-
effectiveness results reﬂects the increased cost of an active treatment when compared 
with a low cost and ineffective alternative.
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DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA
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OBJECTIVES: Number of studies shown beneﬁcial effect of granulocyte colony-
stimulating factors (G-CSF) on neutropenia duration in children receiving chemo-
therapy for leukemia. The aim of present analysis was to assess cost-effectiveness of 
lenograstim in comparison with ﬁlgrastim in Polish settings (threshold is about 
100,095 PLN). METHODS: Analysis covered time horizon of one chemotherapy 
cycle. A public payer perspective was adopted for cost analysis. The costs included 
were based on Polish NHF reference costs list. Data on time to ANC recovery, number 
of days with fever, length of hospital stay and antibiotics use were obtained from 
randomized controlled trials (RCTs) identiﬁed in the conducted systematic review. 
These included trials on prophylactic G-CSF use as well as trials in which only patients 
with neutropenia were included. Equations describing costs and QALY according to 
neutropenia and fever length, hospital stay and antibiotic use were established. 
RESULTS: Estimated QALY difference between lenograstim and ﬁlgrastim is 0.0011 
(CI95%[0.0006; 0.0016]). Total costs difference between lenograstim and ﬁlgrastim is 
−533 PLN (CI95%[−1,052; −28]) Probability of lenograstim being cost-effective over 
ﬁlgrastim is 99.16%. Taking into account only trials where G-CSFs were used in 
neutropenia prophylaxis estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0014 (CI95%[0.0008; 0.0020]). Total costs difference between lenograstim and 
ﬁlgrastim is −699 PLN (CI95%[−1,376; −32]). Probability of lenograstim being cost-
effective over ﬁlgrastim is 98.98%. CONCLUSIONS: Lenograstim is dominant over 
ﬁlgrastim. Acknowledgements: This analysis was supported by Sanoﬁ-Aventis.
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PREPARATION FOR AN AUTOLOGOUS HEMATOPOIETIC STEM CELL 
TRANSPLANTATION ON PATIENTS WITH NON HODGKIN’S 
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OBJECTIVES: To estimate the average and incremental cost effectiveness ratios for 
the plerixafor+GCSF treatment, compared to just a GCSF, in preparation for an 
autologous hematopoietic stem cell transplantation on patients with Non Hodgkin’s 
Lymphoma from the institutional perspective in the Mexican context. METHODS: 
Cost-effectiveness analysis by using a decision tree, to compare the costs and results 
of using a Granulocyte-Colony Stimulating Factor vs. GCSF and plerifaxor, from the 
institutional perspective. A 2 year temporal horizon was considered. The effectiveness 
measurement used, took into consideration the percentage of patients that survive the 
transplantation or graft and was obtained from published medicine based clinical 
studies. Only direct medical costs taken from the mexican health system were evalu-
ated. A 5% discount rate was taken into account and a univariated sensitivity analysis 
using relevant variables was summarized in seven scenarios. RESULTS: The GCSF + 
plerixafor treatment demonstrated the least average cost per transplanted patient with 
US$33,291 vs. US$39,768 for treatment with GCSF (1 USD = 13.5MXN) . According 
to the model, effectiveness in relation to the survival of transplanted patients after 2 
